© 2024 Myocardial Solutions Inc. All rights reserved.
MORRISVILLE, N.C., June 9, 2021 – Most of the funds were raised from individuals and family offices. The Company’s post financing valuation is $93.2M.
Among the business consequences of COVID has been the inability to meet with physicians and hospitals to raise awareness of MyoStrain. As in the US, Spain has suffered significantly with COVID, and the hospitals have been strained to provide care. These have been challenging times to commercialize. This financing will help MSI to market and commercialize MyoStrain in a potentially more receptive post-COVID marketplace.
PR@myocardialsolutions.com
919.677.8100
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.
808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100
© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM
Score are among the trademarks of Myocardial Solutions.
